Expert Interview
Q2 update: Discussing the expanded label for Amvuttra, and commercial outlook for Amvuttra, Vyndaqel and Attruby in Transthyretin amyloid cardiomyopathy (ATTR-CM) with a community cardiologist
Ticker(s): BBIO, ALNY, PFEInstitution: HCA Healthcare
- Cardiologist in practice for over 11 years.
- Currently manages 30 patients that have both nHCM and Chronic Stable Angina.
- Uses eplerenone and spirnolactone currently as 4th line option for hypertension
How do you view Attruby compared to Vyndaqel?
Added By: wilson_adminHow do you view Amvuttra versus the oral options?
Added By: wilson_adminWhat are your thoughts on some of the investigational therapies, i.e. eplontersen and Nex-Z
Added By: wilson_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
